EXPERT

31 March 2020

Purpose

The purpose of this study is to see whether a specialised laboratory test (Prosigna (PAM50) Assay) of breast cancer tissue can be used to choose wāhine / women who can safely avoid radiation therapy because there is a low risk of the cancer coming back.

The EXPERT trial presents a unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence.

Scientific Title

Protocol ANZ 1601/BIG 16-02: A randomised phase III trial of adjuvant radiation therapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised luminal A early breast cancer.

Background

The current standard of care for patients with early breast cancer is radiation therapy after breast conserving surgery to improve local control and survival. However, breast cancer is a complex disease and the benefit of radiation therapy in individual patients varies substantially.

Using the current approach potentially may lead to overtreatment for a substantial proportion of patients and unnecessary treatment toxicity, financial costs and logistical challenges for patients.

Enrolment

EXPERT is an international clinical trial, let by Breast Cancer Trials. It will enrol 1170 patients and is open to wāhine / women aged 50 years or older, with Hormone Receptor (HR) positive, Human Epidermal Growth Factor Receptor 2 (HER2) negative, early stage breast cancer.

Ask your Breast Surgeon or Oncologist if this trial is suitable for you.